A PE-backed medical technology company in Oxford specialising in organ preservation has completed a $142m primary and secondary equity financing.
The oversubscribed round was led by new investor HealthQuest Capital with support from existing OrganOx investors BGF and Lauxera Capital Partners, along with additional new investors Sofina ...
We apologize, but this video has failed to load. “Organ disease and failure represent a large unmet need in healthcare, and we are excited to partner with HealthQuest Capital and the outstanding ...
Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it will effect a 1-for-11 reverse stock split of the Company’s ...
Financing strengthens OrganOx to expand its leadership position in organ technologyOXFORD, United Kingdom and MADISON, N.J., Feb. 24, 2025., a leading organ medical technology company, successfully co ...
GlobalData on MSN1d
OrganOx raises $142m to accelerate growth of metra platform technologyOrganOx 's metra normothermic machine perfusion platform gained approval in Australia, Europe, Canada, and the US.
OrganOx announced today that it completed a $142 million primary and secondary equity financing to accelerate growth opportunities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback